Evidence map›Paper›PMID 33453341›Full record

ReviewBehavioural brain research2021

Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Tyler R Prestwood, Roshanak Asgariroozbehani, Sally Wu, Sri Mahavir Agarwal, Ryan W Logan, Jacob S Ballon, Margaret K Hahn, Zachary Freyberg

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Behavioural brain research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Tyler R PrestwoodDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Roshanak AsgariroozbehaniCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Sally WuCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Sri Mahavir AgarwalCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre (BBDC), University of Toronto, Toronto, ON, Canada.
Ryan W LoganDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA; Center for Systems Neurogenetics of Addiction, The Jackson Laboratory, Bar Harbor, ME, USA.
Jacob S BallonDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Margaret K HahnCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre (BBDC), University of Toronto, Toronto, ON, Canada. Electronic address: margaret.hahn@camh.ca.
Zachary FreybergDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: freyberg@pitt.edu.
Centre for Addiction and Mental Health · CAStanford University · USBoston University · USUniversity of Pittsburgh · US

Funding

Cell-type specific role of circadian-dependent transcription in fentanyl-induced synaptic and behavioral plasticity - SupplementR01HL150432 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LOGAN, RYAN W · 2019 to 2020
$2.0M
Novel dopaminergic mechanisms of islet hormone secretion and antipsychotic drug-induced metabolic disturbancesR01DK124219 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREYBERG, ZACHARY · 2021 to 2023
$1.2M
Mechanisms for Preserving Neurons in Alzheimer's Disease-Related Dementias Across Drosophila and Mouse ModelsR21AG068607 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREYBERG, ZACHARY · 2020 to 2021
$430k
NHLBI NIH HHS R01 HL150432NIA NIH HHS R21 AG068607NIDDK NIH HHS R01 DK124219
6 · The paper itself

Abstract

Schizophrenia is a debilitating psychiatric illness that remains poorly understood. While the bulk of symptomatology has classically been associated with disrupted brain functioning, accumulating evidence demonstrates that schizophrenia is characterized by systemic inflammation and disturbances in metabolism. Indeed, metabolic disease is a major determinant of the high mortality rate associated with schizophrenia. Antipsychotic drugs (APDs) have revolutionized management of psychosis, making it possible to rapidly control psychotic symptoms. This has ultimately reduced relapse rates of psychotic episodes and improved overall quality of life for people with schizophrenia. However, long-term APD use has also been associated with significant metabolic disturbances including weight gain, dysglycemia, and worsening of the underlying cardiometabolic disease intrinsic to schizophrenia. While the mechanisms for these intrinsic and medication-induced metabolic effects remain unclear, inflammation appears to play a key role. Here, we review the evidence for roles of inflammatory mechanisms in the disease features of schizophrenia and how these mechanisms interact with APD treatment. We also discuss the effects of common inflammatory mediators on metabolic disease. Then, we review the evidence of intrinsic and APD-mediated effects on systemic inflammation in schizophrenia. Finally, we speculate about possible treatment strategies. Developing an improved understanding of inflammatory processes in schizophrenia may therefore introduce new, more effective options for treating not only schizophrenia but also primary metabolic disorders.

Indexed as

Antipsychotic AgentsCytokinesHumansInflammationMetabolic DiseasesSchizophreniaAntipsychotic AgentsCytokinesAntipsychotic drugsCytokinesInflammationMetabolismSchizophrenia

Identifiers

PMID33453341
PMCPMC7882027
OpenAlexW3119693776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.